Ulcerative Colitis is a chronic, or long lasting, disease that causes inflammation—irritation or swelling—and sores called ulcers on the inner lining of the large intestine. It is a chronic inflammatory disease of the gastrointestinal (GI) tract, called inflammatory bowel disease (IBD). It most often begins gradually and can become worse over time. Symptoms can be mild to severe. Most people have periods of remission—times when symptoms disappear—that can last for weeks or years. The goal of care is to keep people in remission long term.

 

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some Key Facts of Ulcerative Colitis Market:

• The Ulcerative Colitis market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 9.5%.
• In the United States, the total number of prevalent cases of Ulcerative Colitis were 1,008,823 in the year 2020 which are projected to grow during the forecast period, i.e., 2021–2030.
• In the year 2020, the total prevalent cases of Ulcerative Colitis were 1,008,493 in EU-5, which are expected to grow during the forecast period, i.e., 2021–2030.
• In Japan, the total number of prevalent cases of Ulcerative Colitis was 184,515 in the year 2020 which are anticipated to increase during the forecast period, i.e., 2021–2030.
• Ulcerative Colitis can begin at any age, symptoms develop before age 30 in most individuals that have Ulcerative Colitis. There tend to be two main groups of patients with colitis-late teens through the mid-20s, and then the second peak occurs somewhere after age 50. In the 7MM, the age-specific diagnosed prevalent cases of Ulcerative Colitis were 946,787, 441,834, 173,578, and 15,780 for the age-groups 18-44, 45-64, 65-84, and ≥85 years, in 2020.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

 

Ulcerative Colitis Market Report Key Highlights:

• Ulcerative Colitis market report covers a descriptive overview and comprehensive insight of the Ulcerative Colitis epidemiology and Ulcerative Colitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
• Ulcerative Colitis market report provides insights on the current and emerging therapies.
• Ulcerative Colitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
• Ulcerative Colitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ulcerative Colitis market.

 

Ulcerative Colitis Signs and Symptoms are diarrhea with blood or pus and abdominal discomfort. Other signs and symptoms include: an urgent need to have a bowel movement; feeling tired; nausea or loss of appetite; weight loss; fever; Anemia.

The exact cause of UC is unknown. Researchers believe the following factors may play a role in causing ulcerative colitis: overactive intestinal immune system; genes; environment.

The severity of Ulcerative Colitis is classified as:

• mild-to-moderate

• moderate-to-severe

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

 

Some of the key Ulcerative Colitis Companies:

• Boehringer Ingelheim
• AbbVie
• Arena Pharmaceuticals
• Eli Lilly and Company
• Gilead Sciences and Galapagos NV
• Celgene (Bristol-Myers Squibb)
• Janssen (Johnson & Johnson)
• Theravance Biopharma and Janssen (Johnson & Johnson)
• Landos Biopharma
• Bristol-Myers Squibb
• Gilead Sciences
• Pfizer and Philogen
• Pfizer
• Reistone Biopharma
• AbGenomics (AltruBio)
• And Many Others

 

“According to DelveInsight, Ulcerative colitis affects males and females in equal numbers.”

 

Ulcerative Colitis Drugs Covered:

• Skyrizi (Risankizumab)
• Rinvoq (ABT 494; Upadacitinib)
• Etrasimod (APD334)
• Mirikizumab (LY-3074828)
• Jyseleca (GS-6034; Filgotinib)
• Zeposia (RPC1063; Ozanimod)
• Tremfya (Guselkumab)
• Izencitinib (TD-1473/JNJ 8398)
• BT 11
• Deucravacitinib (BMS-986165)
• GS-4875
• PF-06687234 (Dekavil)
• Ritlecitinib (PF-06651600)/ Brepocitinib (PF-06700841)
• SHR 0302
• AbGn-168H (Neihulizumab)
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Ulcerative Colitis

3. Competitive Intelligence Analysis for Ulcerative Colitis

4. Ulcerative Colitis: Market Overview at a Glance

5. Ulcerative Colitis: Disease Background and Overview

6. Patient Journey

7. Ulcerative Colitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Ulcerative Colitis Treatment and Management

8.2. Ulcerative Colitis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Ulcerative Colitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Ulcerative Colitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Ulcerative Colitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market